Anavex Life Sciences Corp. (AVXL) stock
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 28, 2026Score 6/30
$0.74−0.08 (-9.49%)
Close on Nov 17, 2026Market cap $68.60MP/E –Yield –
Anavex Life Sciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2014 it was -$2.97M. The highest annual figure on record is -$2.14M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2014 | Sep 30, 2014 | -$2.97M | – |
| FY2013 | Sep 30, 2013 | -$2.14M | – |
| FY2012 | Sep 30, 2012 | -$4.32M | – |
| FY2011 | Sep 30, 2011 | -$6.18M | – |
| FY2010 | Sep 30, 2010 | -$5.65M | – |
See a number that looks wrong?